Literature DB >> 22033583

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Thomas C Baghai1, Pierre Blier, David S Baldwin, Michael Bauer, Guy M Goodwin, Kostas N Fountoulakis, Siegfried Kasper, Brian E Leonard, Ulrik F Malt, Dan Stein, Marcio Versiani, Hans-Jürgen Möller.   

Abstract

Current gold standard approaches to the treatment of depression include pharmacotherapeutic and psychotherapeutic interventions with social support. Due to current controversies concerning the efficacy of antidepressants in randomized controlled trials, the generalizability of study findings to wider clinical practice and the increasing importance of socioeconomic considerations, it seems timely to address the uncertainty of concerned patients and relatives, and their treating psychiatrists and general practitioners. We therefore discuss both the efficacy and clinical effectiveness of antidepressants in the treatment of depressive disorders. We explain and clarify useful measures for assessing clinically meaningful antidepressant treatment effects and the types of studies that are useful for addressing uncertainties. This includes considerations of methodological issues in randomized controlled studies, meta-analyses, and effectiveness studies. Furthermore, we summarize the differential efficacy and effectiveness of antidepressants with distinct pharmacodynamic properties, and differences between studies using antidepressants and/or psychotherapy. We also address the differential effectiveness of antidepressant drugs with differing modes of action and in varying subtypes of depressive disorder. After highlighting the clinical usefulness of treatment algorithms and the divergent biological, psychological, and clinical efforts to predict the effectiveness of antidepressant treatments, we conclude that the spectrum of different antidepressant treatments has broadened over the last few decades. The efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly. Further optimization of treatment can be helped by clearly structured treatment algorithms and the implementation of psychotherapeutic interventions. Modern individualized antidepressant treatment is in most cases a well-tolerated and efficacious approach to minimize the negative impact of otherwise potentially devastating and life-threatening outcomes in depressive disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033583     DOI: 10.1007/s00406-011-0259-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  463 in total

1.  Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials.

Authors:  Florian Seemüller; Hans-Jürgen Möller; Michael Obermeier; Mazda Adli; Michael Bauer; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Rebecca Schennach-Wolff; Verena Henkel; Michael Riedel
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

2.  A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

Authors:  S A Montgomery; J G Rasmussen; P Tanghøj
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

3.  Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study.

Authors:  P Kragh-Sørensen; B Müller; J V Andersen; D Buch; K B Stage
Journal:  J Clin Psychopharmacol       Date:  1995-08       Impact factor: 3.153

4.  A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function.

Authors:  Kristen Carreira; Mark D Miller; Ellen Frank; Patricia R Houck; Jennifer Q Morse; Mary Amanda Dew; Meryl A Butters'; Charles F Reynolds
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

5.  Is the antidepressive effect of second-generation antidepressants a myth?

Authors:  P Bech
Journal:  Psychol Med       Date:  2010-02       Impact factor: 7.723

6.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

7.  [Elements for the effective treatment of patients with depressive disorders at the primary care level].

Authors:  U Hegerl; T Pfeiffer-Gerschel; D Althaus
Journal:  MMW Fortschr Med       Date:  2004-05-24

Review 8.  Combined pharmacotherapy and psychological treatment for depression: a systematic review.

Authors:  Sandro Pampallona; Paola Bollini; Giuseppe Tibaldi; Bruce Kupelnick; Carmine Munizza
Journal:  Arch Gen Psychiatry       Date:  2004-07

Review 9.  Diagnostic guidelines for bipolar depression: a probabilistic approach.

Authors:  Philip B Mitchell; Guy M Goodwin; Gordon F Johnson; Robert M A Hirschfeld
Journal:  Bipolar Disord       Date:  2008-02       Impact factor: 6.744

Review 10.  Antidepressants versus placebo for depression in primary care.

Authors:  Bruce Arroll; C Raina Elley; Tana Fishman; Felicity A Goodyear-Smith; Tim Kenealy; Grant Blashki; Ngaire Kerse; Stephen Macgillivray
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  10 in total

Review 1.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

2.  Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.

Authors:  Robert C Hilton; Manivel Rengasamy; Brandon Mansoor; Jiayan He; Taryn Mayes; Graham J Emslie; Giovanna Porta; Greg N Clarke; Karen Dineen Wagner; Boris Birmaher; Martin B Keller; Neal Ryan; Wael Shamseddeen; Joan Rosenbaum Asarnow; David A Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-04-04       Impact factor: 8.829

3.  Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.

Authors:  M Julia García-Fuster; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2016-06-03       Impact factor: 4.530

Review 4.  Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements.

Authors:  Arif Khan; Kaysee Fahl Mar; Walter A Brown
Journal:  Psychopharmacol Bull       Date:  2021-06-01

5.  Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.

Authors:  Lina Chiuccariello; Robert G Cooke; Laura Miler; Robert D Levitan; Glen B Baker; Stephen J Kish; Nathan J Kolla; Pablo M Rusjan; Sylvain Houle; Alan A Wilson; Jeffrey H Meyer
Journal:  Int J Neuropsychopharmacol       Date:  2015-08-27       Impact factor: 5.176

6.  Exploring patients' treatment journeys following randomisation in mental health trials to improve future trial conduct: a synthesis of multiple qualitative data sets.

Authors:  Katrina M Turner; John Percival; David Kessler; Jenny Donovan
Journal:  Trials       Date:  2017-06-15       Impact factor: 2.279

7.  Neurobiological and pharmacological arguments for customization of cognitive behavioral psychotherapy in the treatment of major depressive disorder.

Authors:  Silvia Ristea; Ramona Adriana Schenker; Puiu Olivian Stovicek; Mihail Cristian Pîrlog; Dragoş Marinescu
Journal:  Rom J Morphol Embryol       Date:  2021 Jul-Sep       Impact factor: 0.833

8.  Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Authors:  J Craig Nelson; Zia Rahman; Kimberly K Laubmeier; James M Eudicone; Robert D McQuade; Robert M Berman; Ronald N Marcus; Ross A Baker; John J Sheehan
Journal:  CNS Spectr       Date:  2014-03-18       Impact factor: 3.790

9.  Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation.

Authors:  Shane J McInerney; Heather E McNeely; Joseph Geraci; Peter Giacobbe; Sakina J Rizvi; Amanda K Ceniti; Anna Cyriac; Helen S Mayberg; Andres M Lozano; Sidney H Kennedy
Journal:  Front Hum Neurosci       Date:  2017-02-24       Impact factor: 3.169

Review 10.  Lateral Habenula Gone Awry in Depression: Bridging Cellular Adaptations With Therapeutics.

Authors:  Alvaro Nuno-Perez; Anna Tchenio; Manuel Mameli; Salvatore Lecca
Journal:  Front Neurosci       Date:  2018-07-23       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.